Data show how AbCellera is expanding the reach of T-cell engagers with:
CD3-binding antibodies that consistently generate T-cell engagers with potent tumor-cell killing and low cytokine release.
AbCellera (ABCL) Presents Data on T-Cell Engagers Against Four Tumor Targets at AACR 2024 streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AbCellera and Biogen Inc. have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in.
AbCellera Announces Resignation of Board Member streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Total revenue of $38 million, compared to $485 million in FY 2022Total cumulative partner-initiated program starts with downstreams of 87, with 12 new starts in the yearNet loss of $0.51 per share on a basic and diluted basis, compared to earnings of $0.56 (basic) and $0.50 (diluted) per share in 2022VANCOUVER, Brit.